Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D6O2PN
|
|||
| Drug Name |
ATIR101
|
|||
| Drug Type |
Cell therapy
|
|||
| Indication | Acute lymphoblastic leukaemia [ICD-11: 2A85; ICD-10: C91.0] | Phase 3 | [1] | |
| Acute myeloid leukaemia [ICD-11: 2A60; ICD-9: 205] | Phase 3 | [1] | ||
| Myelodysplastic syndrome [ICD-11: 2A37; ICD-9: 238.7] | Phase 3 | [1] | ||
| Company |
Kiadis Pharma
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02999854) Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer (HATCY). U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.